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Figure 2: (A) The HPA axis; (B) Distance (m) traveled in an open field among Tat (-) and Tat (+) mice acutely-administered saline (0.9%) or oxycodone
3 mg/kg; n=8-9). (C) Circulating corticosterone (ng/mL; n=8-9). § indicates an interaction wherein oxycodone-administered Tat (+) mice in panel B differ
from all other groups; † indicates an interaction wherein oxycodone-administered Tat (-) mice in panel B differ from all other groups. * indicates an
interaction wherein saline-administered Tat (+) mice differ from respective Tat (-) controls in panel C. † indicates a 3-way interaction wherein the Tat (-)
mice differs from all other groups, except from each other in panel C, ‡ indicates a 3-way interaction wherein Tat (+) mice differs from all other groups,
except its respective Tat (-) control, p < 0.05
Antalarmin and/or RU-486 attenuated combined Tat and oxycodone mediated  psychomotor 
behavior,  and influenced circulating steroids 
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Abstract
Human immunodeficiency virus (HIV) is associated with co-morbid affective
and stress-sensitive neuropsychiatric disorders (collectively referred to as
neuroHIV) that afflict ~50% of infected individuals. One factor that may
contribute to neuropathology is the HIV-1 regulatory protein, trans-activator
of transcription (Tat), which promotes anxiety-like behavior that may be
exacerbated by opioid use/abuse. Our prior findings show that conditional
expression of HIV-1 Tat in transgenic mice interacts with acute oxycodone
administration to activate the hypothalamic-pituitary-adrenal (HPA) stress
axis, concurrent with psychomotor/affective dysfunction. Tat-mediated
effects on opioid responding may facilitate vulnerability to stress-related
disorders that impact substance use. We hypothesized that HPA dysregulation
may contribute to HIV-1 Tat-mediated interactions with oxycodone. When
administered acutely, oxycodone (3 mg/kg) increased psychomotor behavior
in an open field and these effects were greater in transgenic mice that
conditionally-expressed the HIV-1 Tat protein [Tat(+)] compared to their
control counterparts [Tat(-)]. Similar to observations in HIV+ patients, Tat(+)
mice demonstrated greater circulating corticosterone than did Tat(-) controls
at baseline. However, Tat(+) mice mounted an insufficient corticosterone
response to stress when exposed to oxycodone challenge. Furthermore, Tat
expression and/or oxycodone administration produced increased anxiety-like
effects in a light-dark transition task. The CRF1 receptor antagonist,
Antalarmin, and GR receptor antagonist, RU-486 attenuated Tat’s capacity to
potentiate oxycodone psychomotor effects. Thus, actions of Tat protein may
underlie HIV-1 mediated HPA dysfunction and the incapacity to mount an
appropriate stress response may influence the effects of clinical opioids on
neuroHIV-related behavior.
Hypotheses
• In vivo, HIV-1 Tat and oxycodone will interact to potentiate
psychomotor and anxiety-like behavior involving
hypothalamic-pituitary-adrenal (HPA) axis activation.
• Antalarmin and/or RU-486 may attenuate combined Tat
and oxycodone psychomotor behavior.
Methods
Animal Subjects: Transgenic mice were bred in the vivarium at the University of Mississippi
(University, MS). Tat (+) mice expressed a Tat 1-86 protein that became transcriptionally-
active in the presence of doxycycline (induced via doxycycline injection, 30mg/kg/d for 5d).
Tat (-) mice expressed on the transcription factor necessary to activate transgene induction,
but did not express the transgene itself. Anxiogenic effects of Tat induction have been
previously-observed using these mice . Mice were kept in a temperature- and humidity-
controlled environment on a 12:12 h light:dark cycle (lights off at 09:00 h) with ad lithium
access to food and water.
Behavioral Assessment: Mice were behaviorally-tested in open field and light dark transition
task. All tests were completed within 8 days of doxycycline induction and occurred 2-3 h into
the dark phase of the light cycle. Data were encoded by an ANY-maze behavioral tracking
system (Stoelting Co., Wood Dale, IL).
Chemicals: Tat 1-86 was induced in transgenic mice [Tat (+) or Tat (-)] via doxycycline
injection (30 mg/kg, i.p.; Cayman Chemical, Ann Arbor, MI). Antalarmin (20 mg/kg, i.p.;
7 days Cayman Chemical, Ann Arbor, MI) and/or Mifepristone (20 mg/kg, i.p.; 8 days
Cayman Chemical, Ann Arbor, MI) Oxycodone was diluted to concentration in sterile saline
(0.9%) and administered once (3 mg/kg, i.p.) 15 min prior to testing..
Enzyme-linked immunosorbent assay (ELISA): Circulating corticosterone was assessed via
ELISA kit per manufacturer instructions (Neogen Life Sciences). Plates were read on a
CLARIOstar microplate reader (BMG Labtech Inc., Cary, NC).
HIV-1 Tat  and/or Oxycodone potentiated psychomotor and anxiety-like behavior and produced 
adrenal insufficiency 
Figure 1: Tat1-86 was induced in Tat (+) and not induced in Tat (-) via doxycycline injection (30mg/kg for 5 d) (n=8-12). Saline or oxycodone (3mg/kg) were
administered 15 minutes prior to behavior testing and assessed in an open field (n = 8-12) and a light/dark transition task (n=7-12);(A) Distance (m) traveled in
an open field. (B) The time spent in light chamber of light-dark transition task; (C) Circulating corticosterone (ng/mL; n=8-10). # indicates a main effect of
genotype wherein Tat (+) mice differ from Tat (-) controls in panel A and B. * indicates interaction wherein saline administered Tat (+) mice differ from






• Tat expression and/or oxycodone greatly
potentiated psychostimulatory effects
compared to respective controls (Fig. 1A).
• Tat caused an increase in anxiety-like behavior
in mice, with significantly less time spent in
light zone (Fig. 1B).
• Tat increased circulating corticosterone than
did Tat(-) controls at baseline, however Tat (+)
mounted an insufficient corticosterone response
to oxycodone challenge indicative of adrenal
insufficiency (Fig. 1C).
• Antalarmin and/or RU-486 attenuated
combined Tat and Oxycodone psychomotor
behavior (Fig. 2B).
• RU-486 potentiated circulating CORT levels,
but Tat and/or oxycodone exposure failed to
produce higher levels indicative of secondary
adrenal insufficiency (Fig. 2C).
Conclusions
HIV and clinical opioids can interact to 
activate stress pathways, influencing 
psychomotor and affective behavior which may 
be correlated with HPA axis dysregulation. 
Antalarmin and RU-486 were able to attenuate 
the psychomotor behavior indicating the 
involvement of CRF and GR receptor as 
potential targets for neuroHIV behavior in HIV 
infected population.
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